I have thoroughly verified the paper content against all reviewer claims. Let me now produce the final consolidated review.

## Summary

This paper proposes using synthetic data as a validation set (rather than only for training augmentation) to improve model checkpoint selection and reduce overfitting in medical image segmentation. Using a modeling-based synthetic tumor generator applied to healthy CT volumes, the authors demonstrate that a synthetic-tumor validation set selects better checkpoints than a small real-tumor validation set. They further introduce a "continual learning" framework where models are trained on dynamically generated synthetic tumors and validated on synthetic data, reporting consistent improvements in liver tumor segmentation DSC and sensitivity for tiny tumors (<5mm radius).

## Strengths

- **Synthetic validation selects checkpoints that closely match test-set optimal.** Figure 3 shows the checkpoint chosen by the synthetic-tumor validation set (150 volumes from cohort 5) aligns almost perfectly with the gold-standard test-set optimum for both in-domain (LiTS) and out-domain (FLARE'23) evaluations, whereas the real-tumor validation set (5 volumes from cohort 2) selects a clearly suboptimal checkpoint. Figures 2 and 3 use the same training data (LiTS training set), so this comparison cleanly isolates the validation effect.

- **Statistically significant DSC improvements from the full framework.** Table 1 reports DSC improvements from 26.7% to 34.5% (in-domain) and 31.1% to 35.4% (out-domain) with non-overlapping 95% confidence intervals from 10 runs. These gains combine the training and validation benefits of synthetic data.

- **Notable sensitivity gains for tiny tumors.** Figure 6 shows sensitivity for tumors <5mm radius improving from ~33% to ~55% on the in-domain test set and ~34% to ~52% on the out-domain test set. Early detection of small tumors is a clinically relevant capability that is difficult to train for with scarce real data.

- **Methodologically grounded tumor generator.** Section 3.2 describes a four-step pipeline (location selection via vessel segmentation, ellipsoidal shape with elastic deformation, Gaussian-noise texture, and post-processing including mass effect) grounded in LI-RADS clinical criteria rather than relying on a black-box generative model.

- **Multi-domain evaluation across five public datasets.** The study uses LiTS, CHAOS, BTCV, Pancreas-CT, and FLARE'23 spanning multiple hospitals and acquisition protocols, with a separate 120-volume out-domain test set from FLARE'23.

## Weaknesses

### Fatal
None.

### Major

- **Validation advantage is confounded with dataset scale.** The core comparison pits a 5-volume real validation set (cohort 2) against a 150-volume synthetic validation set (cohort 5 — 50 healthy CTs × 3 tumor sizes). The benefit could be driven by the 30× increase in validation size rather than anything unique to synthetic data. A proper control would compare synthetic and real validation sets of the same size (e.g., 5 synthetic volumes vs 5 real volumes). The paper does not run this control and does not discuss the confound. This does not invalidate the practical contribution — synthetic data enables large-scale validation when real data is scarce — but the claim that "synthetic data can significantly diversify the validation set" (abstract) and the causal framing over-interpret what the evidence supports. The paper should acknowledge this confound and reframe the contribution as: synthetic data enables *large-scale* validation without sacrificing training data.

- **Table 1 conflates training and validation effects.** The main result table compares (real training + real validation) against (synthetic training + synthetic validation), so the reader cannot attribute the 7.8 DSC point improvement (in-domain) to better training, better validation, or both. While Figures 2 and 3 partially address this by fixing training and varying validation, Table 1 — presented as the headline result — does not include rows that isolate each factor (e.g., train on real + validate on synthetic; train on synthetic + validate on real). Adding these ablations would substantially strengthen the paper.

### Minor

- **Early cancer detection claim is incompletely supported.** Sensitivity for tiny tumors (<5mm) is reported without specificity, false positive rate, or DSC for this subgroup. Sensitivity alone is clinically ambiguous — high sensitivity could be achieved alongside many false positives. Figure 6 shows only point estimates with no error bars or confidence intervals, unlike the DSC results in Table 1. Since the paper emphasizes clinical value ("early detection of cancer"), these omissions weaken the claim. Reporting DSC or FPR for small tumors and adding confidence intervals to Figure 6 would address this.

- **"Continual learning" terminology is overclaimed.** The framework trains on a fixed pool of 25 healthy CT volumes with synthetic tumors generated on the fly each epoch. There are no sequential domain introductions, no evaluation of forgetting, and the data distribution does not change over time in a controlled way — the model simply sees varying synthetic tumors from the same pool of healthy volumes. Comparing this to "static training on real data" is a valid experiment, but calling it "continual learning" (domain-incremental or otherwise) and claiming it as "a novel continual learning framework" (Finding 3 in the introduction) overstates what is demonstrated. The paper would be more accurate describing this as dynamic training with synthetic data augmentation.

- **No direct validation of synthetic tumor realism in this paper.** The approach relies entirely on the tumor generator from prior work (hu2023label). While citing prior validation is standard, the paper's central claims depend on synthetic tumors being good proxies for real ones in the validation set. A simple distribution comparison (size, shape, attenuation statistics) between the generated tumors and real LiTS tumors would strengthen reader confidence.

### Trivial
None.

## Nice-to-Haves

- An ablation for Table 1 that separates training and validation effects (train on real + validate on synthetic; train on synthetic + validate on real) would cleanly attribute the source of improvements.
- The sensitivity results in Figure 6 would benefit from confidence intervals or error bars, consistent with the DSC reporting in Table 1.
- A controlled experiment comparing a synthetic validation set of the same size as the real one (e.g., 5 volumes) would help distinguish the effect of synthetic nature from the effect of scale.

## Removed Points

- **"No validation of synthetic tumor realism beyond prior work"** → This is standard practice (citing prior validated work). However, I note it as a minor weakness since the paper's claims heavily depend on realism.
- **"The claim about last-epoch model checkpoint being judicious is unsupported"** → Tangential to the paper's contribution; not a core weakness.
- **"Figures 2/3 don't isolate validation effect"** → This is factually incorrect; both figures use the same training data (LiTS training set) and differ only in validation data. Kept in review as part of the Major weakness about Table 1, but the original framing was too strong.
- **Generic formatting/style criticism** → Removed per parser-error rule.
- **Strength Finder generic strengths** → "This paper addressed an important problem" type statements removed. Only concrete, evidence-backed strengths retained.

## Novel Insights

Beyond the paper's own contributions, an interesting observation emerges from comparing Figures 2 and 3: the synthetic validation set does not just select a better checkpoint — it tracks the test-set performance trajectory shape (the curve's peak location) with high fidelity, while the real validation set selects a peak that diverges from the test optimum. This suggests that the distributional coverage of the synthetic set aligns with the test distribution in a way that the small, domain-matched real validation set does not, which is a non-obvious property worth further investigation.

## Suggestions

1. Run and report the scale-controlled ablation: validate with 5 synthetic volumes (same size as cohort 2) to distinguish synthetic nature from scale effects.
2. Add an ablation to Table 1 separating training and validation factors (train@real+val@synthetic and train@synthetic+val@real).
3. Add specificity or DSC for tiny tumors, and add confidence intervals to Figure 6.
4. Reframe the "continual learning" terminology to "dynamic training with synthetic data" or provide explicit experiments with sequential domain introduction and forgetting metrics if the term is to be retained.
5. Explicitly acknowledge the scale confound in the discussion and clarify that the practical benefit is that synthetic data enables *large-scale* validation.

## Score and Decision

The paper proposes a practical and underexplored application of synthetic data. The central evidence (Figures 2/3) is clean and supports the validation benefit, despite the scale confound. The weaknesses are bounded and addressable — the scale confound can be reframed, missing ablations can be added, and overclaimed terminology can be scaled back. The paper makes a genuine contribution to a real problem (validation set scarcity in medical imaging) with clinically relevant implications.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>